Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the “glucose-corrected” SUV

Hadi, Mohiuddin; Bacharach, Stephen L.; Whatley, Millie; Libutti, Steven K.; Straus, Stephen E.; Rao, V. Koneti; Wesley, Robert; Carrasquillo, Jorge A.

doi:10.1016/j.nucmedbio.2008.02.007

« Previous Next »Nuclear Medicine and Biology
Volume 35, Issue 4 , Pages 441-445, May 2008

Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the “glucose-corrected” SUV☆

Mohiuddin Hadi
- Department of Radiology, University of California, San Francisco, CA, USA
- Corresponding author. Department of Radiology, UCSF, San Francisco, CA 94158, USA. Tel.: +1 301 476 0567; fax: +1 415 353 9421.
Stephen L. Bacharach
- Department of Radiology, University of California, San Francisco, CA, USA
Millie Whatley
- Nuclear Medicine Department, NIH, Bethesda, MD, USA
Steven K. Libutti
- Surgical Branch, National Cancer Institute, NIH, Bethesda, MD, USA
Stephen E. Straus
- Laboratory of Clinical Infectious Diseases, NIAID, NIH, Bethesda, MD, USA
V. Koneti Rao
- Laboratory of Clinical Infectious Diseases, NIAID, NIH, Bethesda, MD, USA
Robert Wesley
- Biostatistics Service, Clinical Center, NIH, Bethesda, MD, USA
Jorge A. Carrasquillo
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, USA

Received 14 June 2007; received in revised form 29 January 2008; accepted 11 February 2008.

Abstract

Introduction

2-Deoxy-2[¹⁸F]fluoro-d-glucose (FDG) positron emission tomography (PET) has an established role in the evaluation of cancer. Generally, tumor uptake and response to treatment are evaluated using the standardized uptake value (SUV). Some authors have proposed correcting SUV for glucose levels. Insulin is also thought to influence tumor uptake by changing uptake in other tissues. However, little attention has been paid to understanding the variability of glucose or insulin during a single PET study.

Method

We studied the biological and instrumental variability of glucose and insulin measurements in 71 nondiabetic patients undergoing FDG-PET studies. Multiple glucose measurements were obtained in all 71 subjects, and in 69 of these 71 subjects, multiple serum insulin measurements were made. We determined the coefficient of observed variation (CV_ow) and the coefficient of variation attributable to biological variability (CV_bv) for both glucose and insulin.

Results

The mean glucose concentration was 78.9±13.5 mg/dl. The mean insulin value was 6.49±5.92 μU/ml. The weighted mean CV_ow and CV_bv was 5.0% and 3.6%, respectively, for glucose and 14.2% and 8.3%, respectively, for insulin.

Conclusions

Variations in the range of 3.6% are observed in glucose measurements during the time course of an FDG scan even after accounting for analytical error; larger variations of 8.3% are observed in insulin levels. Therefore, corrections of SUV for blood glucose, especially if obtained from single measurements, can introduce additional errors of at least this much.

Keywords: PET, PET/CT, Glucose, Insulin, Variability, FDG-PET